Orion, a Finnish pharmaceutical company, had an impressive end of the year, with revenue soaring by 60% in the last quarter compared to the previous year, totaling approximately 695 million euros. This remarkable growth can be attributed largely to a conditional milestone payment of 180 million euros linked to the sales performance of their prostate cancer drug, Nubeqa.

The company's operating profit in this period reached nearly 330 million euros, a substantial increase from about 93 million euros the year prior. The strong financial performance indicates that Orion has effectively capitalized on the market demand for innovative cancer treatments, which may enhance its competitive position in the pharmaceutical industry.

In light of these positive results, Orion has announced an increase in dividends, proposing a payout of 1.80 euros per share. This decision reflects the company’s robust financial health and commitment to returning value to its shareholders, which could further strengthen investor confidence in the company as it continues to navigate the evolving pharmaceutical landscape.